Brawn Biotech Share Price
22.70+0.10 (+0.44%)
-1.94% past 1 Year
Brawn Biotech Ltd is involved in the manufacture of tablets capsules and oral syrups contract manufacture and supply of pharmaceutical products. The company's products are made under various categories namely
Corporate filings & documents
Announcements
Letters sent to shareholders as per Reg 36
1 day agoLetters sent to shareholders as per Reg 36
1 day agoNewspaper Publication for 41st Notice of AGM.
2 days agoNewspaper Publication for 41st Notice of AGM.
2 days agoANNUAL REPORT FOR FY 2025-26
2 days agoANNUAL REPORT FOR FY 2025-26
2 days agoNotice of 41st AGM to be held on 29.09.2026
2 days agoNotice of 41st AGM to be held on 29.09.2026
2 days agoPublication of Un-audited financial results for the quarter ended June 30 2026.
3 weeks agoPublication of Un-audited financial results for the quarter ended June 30 2026.
3 weeks agoOutcome of Board Meeting held on August 13 2026 to consider and approve inter-alia un-audited financial results of the company for quarter ended June 30 2026.
3 weeks agoOutcome of Board Meeting held on August 13 2026 to consider and approve inter-alia un-audited financial results of the company for quarter ended June 30 2026.
3 weeks agoOutcome of Board Meeting held on August 13 2026 to consider and approve inter-alia un-audited financial results of the company for quarter ended June 30 2026.
3 weeks agoOutcome of Board Meeting held on August 13 2026 to consider and approve inter-alia un-audited financial results of the company for quarter ended June 30 2026.
3 weeks agoBrawn Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve Un-Audited Financial Results Of The Company For The Quarter Ended June 30 2026.
4 weeks agoBrawn Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve Un-Audited Financial Results Of The Company For The Quarter Ended June 30 2026.
4 weeks agoCertificate under Reg 74(5)
1 month agoCertificate under Reg 74(5)
1 month agoClosure of Trading Window for the quarter ended June 30 2026.
2 months agoClosure of Trading Window for the quarter ended June 30 2026.
2 months agoNewspaper publication of Audited Financial Results for Quarter and Year ended 31.03.2026
3 months agoNewspaper publication of Audited Financial Results for Quarter and Year ended 31.03.2026
3 months agoIntimation regarding non-applicability of Regulation 23(9)
3 months agoIntimation regarding non-applicability of Regulation 23(9)
3 months agoBSE Intimation for Non-Applicability of Annual Secretarial Compliance Report under Regulation 24A
3 months agoBSE Intimation for Non-Applicability of Annual Secretarial Compliance Report under Regulation 24A
3 months agoThe Board of Directors today in their meeting considered and approved the audited financial results for quarter and year ended 31st March 2026
3 months agoThe Board of Directors today in their meeting considered and approved the audited financial results for quarter and year ended 31st March 2026
3 months agoOutcome of the Board Meeting of the Company held on 29th May 2026 and submissions of Audited Financial Results for the Quarter and year ended 31.03.2026
3 months agoOutcome of the Board Meeting of the Company held on 29th May 2026 and submissions of Audited Financial Results for the Quarter and year ended 31.03.2026
3 months agoBrawn Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve the audited financial results of the Company for the quarter and financial year ended March 31 2026.
3 months agoBrawn Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve the audited financial results of the Company for the quarter and financial year ended March 31 2026.
3 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Brawn Biotech Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L74899DL1985PLC022468</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: PRIYANKA SHARMA <br/> Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: RATI GARG <br/> Designation: CHIEF FINANCIAL OFFICER <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 13/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoCertificate under Reg 74(5) of SEBI (DP) Regulations 2018
4 months agoClosure of Trading Window from 01st April 2026 till 48 hours after the declaration of financial results for the quarter and financial year ended 31st March 2026.
5 months agoClosure of Trading Window from 01st April 2026 till 48 hours after the declaration of financial results for the quarter and financial year ended 31st March 2026.
5 months agoAppointment of Internal Auditors and Secretarial Auditor for FY 2025-26.
5 months agoNewspaper Advertisement for special window for transfer of physical shares.
6 months agoNewspaper publication of Unaudited Financial Results for Quarter and year to date ended 31.12.2025.
6 months agoOUTCOME OF BOARD MEETING HELD ON TODAY
6 months agoUnaudited Financial Results for quarter and nine months ended 31.12.2025
6 months agoUnaudited Financial Results for quarter and nine months ended 31.12.2025
6 months agoPrior Intimation for Board Meeting scheduled to be held on 14th February 2026 to consider and approve unaudited financial results for the quarter ended 31st December 2025.
6 months agoAppointment of Chief Financial Officer.
7 months agoCertificate under Regulation 74(5) of SEBI (DP) Regulations 2018
7 months agoResignation of Ms. Pooja Pandey (CFO and KMP).
8 months agoGeneral Announcement
8 months agoINTIMATION REGARDING CLOSURE OF TRADING WINDOW
8 months agoADDITIONAL DETAILS REQUIRED FOR CORPORATE ANNOUNCEMENT UNDER REGULATION 30
8 months agoDisclosure under regulation 30 of the SEBI (LODR) Regulations for resigantion of Director
9 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
No data available.
Company details
Registered office
1st Floor C-64, Lajpat Nagar - 1 NULL New Delhi Delhi PIN: 110024 Tel No: 011-29815331 Fax No: NULL Email: [email protected] Internet: www.brawnbiotech.com
Registrars
B-25/1, First Floor, Okhla Industrial Area, Phase 2, New Delhi-110 020 B-25/1, First Floor Okhla Industrial Area Phase 2 PIN: Tel No: 91-011 26387320 / 21 Fax No: 91-011 26387322 Email: [email protected]
Management
Mayank Jain, Non Executive Independent Director
Pooja Jha, Non Executive Independent Director
Priyanka Sharma, Company Secretary & Compliance Officer
Details
BSE 530207
NSE NULL
ISIN INE899B01015